KORRO BIO INC (KRRO)

US5009461089 - Common Stock

51.3  +1.05 (+2.09%)

After market: 51.3 0 (0%)

News Image
3 days ago - Korro Bio, Inc.

Korro to Participate in Upcoming June Investor and Scientific Conferences

CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members of management will participate in...

News Image
13 days ago - Korro Bio, Inc.

Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference

KRRO-110 showed sustained editing efficiency of approximately 60% and increased total alpha-1 antitrypsin (AAT) protein levels to greater than 60uM at week...

News Image
19 days ago - InvestorPlace

KRRO Stock Earnings: Korro Bio Beats EPS for Q1 2024

KRRO stock results show that Korro Bio beat analyst estimates for earnings per share the first quarter of 2024.

News Image
19 days ago - BusinessInsider

KRRO Stock Earnings: Korro Bio Beats EPS for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Korro Bio (NASDAQ:KRRO) just reported results for the first quarter of 2024.Kor...

News Image
19 days ago - Korro Bio, Inc.

Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer

On track for regulatory filing for First-in-Human (FIH) study of KRRO-110 in patients with Alpha-1 Antitrypsin Deficiency (AATD) anticipated in the second...

News Image
23 days ago - Market News Video

Korro Bio is Now Oversold (KRRO)

News Image
2 months ago - Korro Bio, Inc.

Korro Announces $70 Million Private Placement

Financing led by Deep Track Capital with participation from other leading healthcare investors Pro-forma cash and cash equivalents of approximately $236...

News Image
2 months ago - Korro Bio, Inc.

Korro to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Chief Executive Officer and President,...

News Image
2 months ago - Korro Bio, Inc.

Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress

On track for regulatory filing for First-in-Human study of KRRO-110 in Alpha-1 Antitrypsin Deficiency (AATD) patients anticipated in the second half of...

News Image
3 months ago - Seeking Alpha

BMO starts Korro at outperform, cites upcoming data for AATD drug (NASDAQ:KRRO)

BMO initiated coverage of Korro Bio (KRRO) with an outperform rating, citing upcoming data for its AATD drug candidate KRRO-110 and potential partnerships. Read more here.

News Image
6 months ago - The Motley Fool

These 3 Biotech Stocks More Than Doubled in November. Can They Fly Even Higher in 2024?

These stocks are coming off a banner month, but what about the road ahead?